The comparison between Zepbound and Wegovy
Recently, Eli Lilly & Co. announced significant results regarding its weight-loss drug, Zepbound. In a comparative study, Zepbound was shown to be more effective than Wegovy, Novo Nordisk’s drug, with participants losing an average of 20% of their body weight in 72 weeks. This equates to about 50 pounds, a remarkable result compared to the 14% weight loss experienced by those who took Wegovy
.
Implications for the health market
These results not only confirm previous studies that suggested a greater impact than Zepbound, but they also offer Eli Lilly an advantageous position in a rapidly growing market. The market for weight-loss drugs is expected to reach 130 billion dollars by the end of the decade. Although Novo Nordisk was the first to launch GLP-1 drugs to combat obesity, Zepbound’s results could change competitive dynamics in the
sector.
Market reactions and future prospects
Novo Nordisk shares fell 1.8% in Copenhagen, while Eli Lilly’s shares rose 2.5% before US markets opened. The side effects associated with both medications were primarily gastrointestinal and similar, suggesting that both treatments have comparable safety profiles. Eli Lilly announced that the full results of the study will be published in a peer-reviewed scientific journal and presented at a medical meeting next year, which could further influence market perception of Zepbound.
